Filing Flows

Filing Flows › 8-K events › Ardent Health

Ardent Health: departure or appointment of directors and officers

Form 8-K filed Oct 23, 2026 · items 5.02

What the filing says

As previously disclosed, Martin J. Bonick’s employment as President and Chief Executive Officer of Ardent Health, Inc. (the “Company”) and his service as a member of the Company’s Board of Directors (the “Board”) ended effective June 2, 2026 (the “Separation Date”).

Read the filing on SEC EDGAR →

What usually followsAcross 39,174 8-Ks reporting Item 5.02 (directors and officers: departures, appointments, pay) in our universe, the stock's median move the next session was −0.1% (typical size ±1.4%, up 48% of the time); over the following 21 sessions, +0.7%. Every item ranked →

What this kind of filing means

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

Ardent Health at a glance

Latest quarterQ3 2026
Revenue$1.6B
Revenue Y/Y+3%
Operating margin5.0%
IndustryServices-General Medical & Surgical Hospitals, NEC

Ardent Health, Q3 2026: revenue $1.6B (+3% year over year), operating margin 5.0%. The chart follows the revenue to costs, profit and cash.

Ardent Health: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent ceo changes

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.